Effect of udenafil administration on postmicturition dribbling in men: a prospective, multicenter, double-blind, placebo-controlled, randomized clinical study

Aging Male. 2020 Dec;23(5):571-578. doi: 10.1080/13685538.2018.1545834. Epub 2019 Jan 16.

Abstract

Purpose: Postmicturition dribbling (PMD) is a stressful symptom in middle-aged men characterized by urinary leakage after the completion of normal voiding. Appropriate treatments have not yet been introduced. This study assessed the efficacy of treatment of PMD with 75 mg udenafil daily.

Materials and methods: The study included 138 men with regular sexual lifestyles. The Hallym PMD questionnaire (HPMDQ) was used to assess PMD symptoms. After all basic examinations, patients were randomly assigned to either udenafil or placebo. Patients completed the surveys, uroflowmetry (UFM), a bladder scan, and the paper test during the follow-up visit.

Results: The mean age of the patients was 57.6 years. PMD with one of every three urinations was experienced by 59 patients (42.8%), whereas 45 patients (32.6%) experienced PMD with two of every three urinations. PMD with every urination was experienced by 34 patients (24.6%). More than half of the patients (89 patients, 65.4%) indicated that persistent PMD symptoms would likely result in moderate to severe discomfort in their daily activities. As time passed, the udenafil group showed significant improvement in PMD symptoms (p = 0.001).

Conclusion: Udenafil 75 mg once daily can be an effective treatment for patients with PMD symptoms.

Keywords: Postmicturition dribbling; lower urinary tract symptoms; phosphodiesterase-5 inhibitors.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Double-Blind Method
  • Humans
  • Male
  • Middle Aged
  • Phosphodiesterase 5 Inhibitors*
  • Prospective Studies
  • Prostatic Hyperplasia*
  • Pyrimidines
  • Sulfonamides
  • Treatment Outcome

Substances

  • Phosphodiesterase 5 Inhibitors
  • Pyrimidines
  • Sulfonamides
  • udenafil